Nat Commun 2016 May 13
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Related Questions
New answer by Medical Oncologist at Memorial Sloan Kettering Cancer Center (November 22, 2019)
I would test if I was considering single agent hormone therapy. I agree with the points raised in @Adam L. Cohen excellent and thorough answer. I would add that the detec...